64 results about "Ziprasidone" patented technology

The subject invention provides methods for treating symptoms and/or conditions associated with idiopathic hyperhidrosis by using compounds that decrease the activity of serotonin 5-HT2C receptors. Compounds that can ameliorate symptoms of idiopathic hyperhidrosis and associated conditions include 5-HT2C receptor antagonists (i.e., ketanserin, ritanserin, mianserin, mesulergine, cyproheptadine, fluoxetine, mirtazapine, olanzapine, and ziprasidone) as well as 5-HT2C receptor modulators (i.e., inverse agonists, partial agonists, and allosteric modulators).

The use of phosphodiesterase 5 (PDE5) inhibitors for treatment of schizophrenia is described. Suitable PDE5 inhibitors for use for treatment of schizophrenia include sildenafil, vardenafil, tadalafil, E-8010, zaprinast, and E-4021. In one embodiment, for example, a method is described for treating schizophrenia in a patient which comprises treating the patient with an effective amount of a PDE5 inhibitor, or a pharmaceutically acceptable salt, solvate, or composition thereof. The PDE5 inhibitor may be administered orally. The PDE5 inhibitor may also be administered together with one or more conventional antipsychotic medications such as risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, clozapine, haloperidol, and fluphenazine.

This invention relates to combinations of an atypical antipsychotic, for example ziprasidone, and a dopamine agonist, kits containing such combinations, pharmaceutical compositions comprising such combinations, and methods of using such combinations to treat patients suffering from psychosis and movement disorders associated with Parkinson's disease and subcortical dementias.

The invention relates to a novel dispersible tablet which is prepared from a certain amount of antipsychotic medicines or pharmaceutically acceptable salt or ester thereof or mixture thereof, a certain amount of selective serotonin reuptake inhibitors (SSRIs) and at least one of pharmaceutically acceptable carriers, wherein the antipsychotic medicines are aripiprazole, fluvoxamine, escitalopram, olanzapine, mirtazapine, clozapine, ziprasidone, mianserin, agomelatine, lurasidone, iloperidone, blonanserin, moclobemide, timiperone, palipeddone, trimipramine, carpipramine, lofepramine or mosapramine. The novel dispersible tablet is used for preventing, delaying or treating depression or schizophrenia of patients. Compared with common tablets or capsules, the novel dispersible tablet has the characteristics of quick and uniform dispersion, short disintegration time, quick medicine absorption, high bioavailability and good stability, and is convenient to take.

Ziprasidone formulations, including controlled-release formulations, formulations containing ziprasidone dihydrochloride, and combinations of ziprasidone and an additional active agent are described.

The invention discloses a method for synchronously detecting seventeen antipsychotics in a blood sample. The method comprises the steps that the sample is extracted with a mixed solution of methanol and acetonitrile to obtain supernate, and after a solvent is removed from the supernate, the supernate is dissolved in a methanol aqueous solution and filtered to obtain a specimen; a high performanceliquid chromatography tandem mass spectrometry method is adopted to detect the specimen; the sample is serum or plasma, and the antipsychotics are amisulpride, aripiprazole, dehydro aripiprazole, chlorpromazine, clozapine, desmethylclozapine, fluphenazine, haloperidol, olanzapine, paliperidone, perphenazine, quetiapine, risperidone, 9-hydroxyrisperidone, sulpiride, ziprasidone and thioridazine; inthe high performance liquid chromatography, a mobile phase A is an aqueous solution of formic acid, and a mobile phase B is a methanol solution of the formic acid; and the mass spectrometry adopts amulti-ion reaction monitoring mode of positive ion electrospray ionization.

A method for minimizing the weight gain side effect associated with ABILIFY® (aripiprazole) or GEODON® (ziprasidone) treatment is disclosed. In this method, metformin, a biguanide compound, is concurrently administered to a patient taking the ABILIFY® (aripiprazole) or GEODON® (ziprasidone) therapy. A pharmaceutical composition containing the combination of ABILIFY® (aripiprazole) or GEODON® (ziprasidone), together with metformin is also disclosed.

A ziprasidone formulation containing at least (a) one ziprasidone compound and at least an excipient component (b) that includes at least one of

• • (i) one or more of a mono-, di-, or tri-ester of C_12-24fatty acids and glycerol, in which each fatty acid group is chosen independently of the others, or mixtures thereof; and/or (ii) one or more mono- or di-esters of C_12-24fatty acids and polyC_2-3alkyleglycol, in which each fatty acid group is chosen independently of the others, or mixtures thereof; and/or (iii) a TPGS (tocopherol-succinic acid-polyethyleneglycol); and where this component (b) may optionally include (iv) optionally free polyC_2-3alkyleglycol; (v) optionally free glycerol; and (vi) optionally free fatty acids having 12-24 carbon atoms; and (vii) mixtures thereof;

the formulation further comprising (c) at least one surfactant selected from anionic and non-ionionic surfactants and still further comprising (d) at least one hydroxylalkyl alkylcellulose in which each alkyl group and each hydroxyalkyl group independently has from 1 to 4 carbon atoms. The formulation achieves improved dissolution and bioavailability of the formulation. Reduction in side effect profile and increased efficacy and utility in additional indications are also disclosed.

The invention relates to a method for detecting the liquid quality of an antipsychotic drug in serum or plasma and pretreatment of a specific purification material of the antipsychotic drug. The method comprises the following steps: a serum or plasma sample is subjected to protein precipitation by a certain proportion of organic reagents; a supernatant obtained through centrifugal precipitation ispretreated with a specific purification material to obtain a purified sample solution, the purified sample solution is subjected to liquid chromatography-tandem mass spectrometry detection and analysis, and eight antipsychotic drugs including olanzapine, clozapine, quetiapine, aripiprazole, flupiperidinol, risperidone, pariperidone and ziprasidone in serum or plasma are detected at the same time.The pretreatment of the specific purification material is a mixed solid-phase extraction column taking silica gel as a matrix, and the blood is purified by the specific purification material, so thatthe interference of the matrix in the blood can be removed, the matrix effect of eight antipsychotic drugs can be improved, and the recovery rate of the antipsychotic drugs can be better ensured.

The invention discloses a making method of qilaxi ketone with structural formula as formula (I), which is characterized by the following: the chemical name of compound is 5-(2-(4-(1,2-benzo isothiazole-3-base)-piperazine) acetyl)-6-chloride-1, 3-dihydrogen-2H-indole-2-ketone, which is reduced in the organic acid solvent; the solvent is C1-C6 paraffin acid substituted by at least one halogenate atom with carboxyl function group.

The present invention provides methods, dosage forms and kits for treating with an effective amount of ziprasidone a CNS disorder in a human when the human is in a fasted state. In one embodiment, the invention relates to a method for treating a CNS disorder in a human, which method comprises administering to the human in a fasted state, a solid oral dosage form comprising an amount of ziprasidone effective to treat said CNS disorder, wherein the area under the serum concentration versus time curve (AUC_0-inf) of the ziprasidone in the human subsequent to said administering is from 70% to 140% of the mean area under the ziprasidone serum concentration versus time curve (AUC_0-inf) resulting from administration of a control ziprasidone immediate release oral capsule containing the same amount of ziprasidone to a cohort of humans in a fed state.

Provided are processes for preparing ziprasidone from 1, 2-benzothiazole-3-piperazinyl (BITP) and 5-(2-chloroethyl)-6-chloro-1, 3-dihydro-indole-2(2H) one (CEI) using various solvents, bases and promoters.

Provided is a crystalline form of ziprasidone base and processes for its preparation.

Provided are processes for preparing ziprasidone from CEI and BIPT.

The invention discloses a method for preparing ziprasidone, which comprises the following steps of: dissolving 5-(2-chloroacetyl)-6-chloro-1,3-dihydro-indol-2-(2H)-one and 3-piperazinyl-1,2-benzisothiazole hydrochloride in a mixed system of a water-soluble polar nonprotonic solvent and an aqueous solution of inorganic base, and reacting at the temperature of between 60 and 70DEG C for 3 to 6 hours; and after the reaction is finished, adding purified water, performing suction filtration, washing, and drying to obtain the ziprasidone. A reaction solvent is a mixed solution of the water-soluble polar nonprotonic solvent and the aqueous solution of the inorganic base, so that the dissolubility of reactants is increased, the acid binding effect is enhanced, and the reaction time is shortened; reaction conditions are concise, the operation is simple and the method is suitable for industrial production; and posttreatment is simple, the product yield is high, and impurity content is low.

The invention relates to a preparation method of a ziprasidone intermediate.The preparation method is a method to prepare 6-chloro-2-indolone by one-pot process, an alkali liquid and phase-transfer catalyst low in price are used in the preparation process to substitute the prior art sodium hydride necessary to use and high in price, recyclable low-grade aliphatic ketone and low-grade fatty alcohol are used to substitute DMF (dimethyl formamide) and DMSO (dimethylsulfoxide) difficult to recycle, the cost is reduced greatly, the materials used herein are cheap and easy to obtain, the process is simple and feasible, posttreatment steps are simplified, particularly the step (1) requires no washing, extracting and purifying operation, one step may be performed directly, the whole operating step needs no use of column chromatography for purification, the whole preparation process is simplified, and the method is convenient to industrialize; in the synthetic process of formula III compound, a deacidifying process is mild and safe; in the synthesis of formula II compound, low-valence sulfur-containing compound is used in reduction, generation of mass waste acid liquid is avoided, production is safe and environment-friendly, and the preparation process is simple and easy.

Ziprasidone base or a pharmaceutically acceptable salt thereof free from colored impurities, in particular those giving the product a “slightly pink to pink” coloration.

Pharmaceutical formulations comprising: a compound selected from the group consisting of ziprasidone, having a maximum average particle size; a carrier; and preferably at least two surface stabilizers are disclosed. The present invention also comprises methods of treating psychosis with such a formulation and processes for making such a formulation.

Compositions comprising ziprasidone free base or a difficult to wet pharmaceutically acceptable ziprasidone acid addition salt, a polysorbate, and colloidal silicon dioxide form good aqueous suspensions having a useful shelf life and are easily re-suspended if setting occurs.

A process for the preparation of ziprasidone and a novel intermediate useful in its preparation. The process comprises the reduction of a compound (III) to give a compound (V) which is then reduced to compound (II). This is reacted with compound (IV) to give the desired compound.

Pharmaceutical formulations of ziprasidone comprise ziprasidone or a salt thereof, in the form of particles having a mean particle size greater than about 90 μm and a pharmaceutically acceptable excipient.